Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

96 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-01-31

Study Completion Date

2008-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was conducted to provide detailed information on the efficacy of indacaterol (in terms of the spirometry assessment forced expiratory volume in 1 second \[FEV1\]) over the full 24-h time period

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT01089127

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE3

Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD)

NCT00792805

Chronic Obstructive Pulmonary Disease (COPD)

COMPLETED PHASE3

Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00677807

COPD

COMPLETED PHASE3

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00624286

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE3

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)

NCT00821093

Chronic Obstructive Pulmonary Disease (COPD)

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease (COPD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Indacaterol Morning,Indacaterol Evening, Salmeterol

In period I, indacaterol 300 μg once a day in the morning delivered via single dose dry powder inhaler (SDDPI) with a placebo to salmeterol delivered via dry powder inhaler (DPI). Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period II, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period III, Salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and second dose in the evening along with placebo matching indacaterol delivered by SDDPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.

Group Type EXPERIMENTAL

Indacaterol

Intervention Type DRUG

300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)

Salmeterol

Intervention Type DRUG

50 µg twice daily delivered via dry powder inhaler (DPI)

Placebo to Indacaterol

Intervention Type DRUG

Placebo matching indacaterol was delivered via SDDPI.

Placebo to Salmeterol

Intervention Type DRUG

Placebo matching salmeterol was delivered via DPI

Indacaterol Evening,Indacaterol Morning, Placebo

In period I, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period II, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period III, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.

Group Type EXPERIMENTAL

Indacaterol

Intervention Type DRUG

300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)

Placebo to Indacaterol

Intervention Type DRUG

Placebo matching indacaterol was delivered via SDDPI.

Placebo to Salmeterol

Intervention Type DRUG

Placebo matching salmeterol was delivered via DPI

Salmeterol, Placebo, Indacaterol Morning

In period I, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose was in the evening along with placebo matching indacaterol delivered by SDDPI. In period II, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period III, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.

Group Type EXPERIMENTAL

Indacaterol

Intervention Type DRUG

300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)

Salmeterol

Intervention Type DRUG

50 µg twice daily delivered via dry powder inhaler (DPI)

Placebo to Indacaterol

Intervention Type DRUG

Placebo matching indacaterol was delivered via SDDPI.

Placebo to Salmeterol

Intervention Type DRUG

Placebo matching salmeterol was delivered via DPI

Placebo, Salmeterol, Indacaterol Evening

In period I, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period II, salmeterol 50 μg twice daily delivered via dry powder inhaler (DPI). One of the two daily doses of salmeterol was administered in the morning and the second dose was in the evening along with placebo matching indacaterol delivered by SDDPI. In period III, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via dry DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.

Group Type EXPERIMENTAL

Indacaterol

Intervention Type DRUG

300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)

Salmeterol

Intervention Type DRUG

50 µg twice daily delivered via dry powder inhaler (DPI)

Placebo to Indacaterol

Intervention Type DRUG

Placebo matching indacaterol was delivered via SDDPI.

Placebo to Salmeterol

Intervention Type DRUG

Placebo matching salmeterol was delivered via DPI

Indacaterol Morning, Placebo, Indacaterol Evening

In period I, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period II, During morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period III, Patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.

Group Type EXPERIMENTAL

Indacaterol

Intervention Type DRUG

300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)

Placebo to Indacaterol

Intervention Type DRUG

Placebo matching indacaterol was delivered via SDDPI.

Placebo to Salmeterol

Intervention Type DRUG

Placebo matching salmeterol was delivered via DPI

Indacaterol Evening,Salmeterol, Indacaterol Morning

In period I, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period II, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period III, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.

Group Type EXPERIMENTAL

Indacaterol

Intervention Type DRUG

300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)

Salmeterol

Intervention Type DRUG

50 µg twice daily delivered via dry powder inhaler (DPI)

Placebo to Indacaterol

Intervention Type DRUG

Placebo matching indacaterol was delivered via SDDPI.

Placebo to Salmeterol

Intervention Type DRUG

Placebo matching salmeterol was delivered via DPI

Salmeterol, Indacaterol Evening, Placebo

In period I, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period II, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period III, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.

Group Type EXPERIMENTAL

Indacaterol

Intervention Type DRUG

300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)

Salmeterol

Intervention Type DRUG

50 µg twice daily delivered via dry powder inhaler (DPI)

Placebo to Indacaterol

Intervention Type DRUG

Placebo matching indacaterol was delivered via SDDPI.

Placebo to Salmeterol

Intervention Type DRUG

Placebo matching salmeterol was delivered via DPI

Placebo, Indacaterol Morning, Salmeterol

In period I, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period II, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via dry powder inhaler DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period III, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.

Group Type EXPERIMENTAL

Indacaterol

Intervention Type DRUG

300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)

Salmeterol

Intervention Type DRUG

50 µg twice daily delivered via dry powder inhaler (DPI)

Placebo to Indacaterol

Intervention Type DRUG

Placebo matching indacaterol was delivered via SDDPI.

Placebo to Salmeterol

Intervention Type DRUG

Placebo matching salmeterol was delivered via DPI

Indacaterol Morning, Salmeterol, Placebo

In period I, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period II, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period III, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.

Group Type EXPERIMENTAL

Indacaterol

Intervention Type DRUG

300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)

Salmeterol

Intervention Type DRUG

50 µg twice daily delivered via dry powder inhaler (DPI)

Placebo to Indacaterol

Intervention Type DRUG

Placebo matching indacaterol was delivered via SDDPI.

Placebo to Salmeterol

Intervention Type DRUG

Placebo matching salmeterol was delivered via DPI

Indacaterol Evening, Placebo, Salmeterol

In period I, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via dry powder inhaler DPI. In period II, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period III, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.

Group Type EXPERIMENTAL

Indacaterol

Intervention Type DRUG

300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)

Salmeterol

Intervention Type DRUG

50 µg twice daily delivered via dry powder inhaler (DPI)

Placebo to Indacaterol

Intervention Type DRUG

Placebo matching indacaterol was delivered via SDDPI.

Placebo to Salmeterol

Intervention Type DRUG

Placebo matching salmeterol was delivered via DPI

Salmeterol, Indacaterol Morning, Indacaterol Evening

In period I, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period II, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period III, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.

Group Type EXPERIMENTAL

Indacaterol

Intervention Type DRUG

300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)

Salmeterol

Intervention Type DRUG

50 µg twice daily delivered via dry powder inhaler (DPI)

Placebo to Indacaterol

Intervention Type DRUG

Placebo matching indacaterol was delivered via SDDPI.

Placebo to Salmeterol

Intervention Type DRUG

Placebo matching salmeterol was delivered via DPI

Placebo, Indacaterol Evening, Indacaterol Morning

In period, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period II, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period III, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.

Group Type EXPERIMENTAL

Indacaterol

Intervention Type DRUG

300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)

Placebo to Indacaterol

Intervention Type DRUG

Placebo matching indacaterol was delivered via SDDPI.

Placebo to Salmeterol

Intervention Type DRUG

Placebo matching salmeterol was delivered via DPI

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Indacaterol

300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)

Intervention Type DRUG

Salmeterol

50 µg twice daily delivered via dry powder inhaler (DPI)

Intervention Type DRUG

Placebo to Indacaterol

Placebo matching indacaterol was delivered via SDDPI.

Intervention Type DRUG

Placebo to Salmeterol

Placebo matching salmeterol was delivered via DPI

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

QAB149 Serevent®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female adults aged ≥ 40 years, who have signed an Informed Consent Form prior to initiation of any study-related procedure
* Co-operative outpatients with a diagnosis of chronic obstructive pulmonary disease (COPD) (moderate to severe as classified by the Global initiative for chronic obstructive lung disease (GOLD) Guidelines, 2006) and:
* Smoking history of at least 20 pack years
* Post-bronchodilator FEV1 \< 80% and ≥30% of the predicted normal value
* Post-bronchodilator FEV1/forced vital capacity (FVC) \< 70%

Exclusion Criteria

* Pregnant or lactating females
* Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to Visit 1 or during the run-in period
* Patients requiring long term oxygen therapy (\>15 h a day)
* Patient who have had a respiratory tract infection 6 weeks prior to V2 (with further criteria)
* Patients with concomitant pulmonary disease, pulmonary tuberculosis, or clinically significant bronchiectasis
* Patients with history of asthma (with further criteria)
* Patients with Type I or uncontrolled type II diabetes.
* Patients who have clinically relevant laboratory abnormalities or a clinically significant abnormality
* Any patient with active cancer or a history of cancer with less than 5 years disease free survival time
* Patient with a history with long QT syndrome or whose QTc interval is prolonged
* Patients with a hypersensitivity to any of the study drugs or drugs with similar chemical structure
* Patients who have had treatment with an investigational drug (with further criteria)
* Patients who have had live attenuated vaccination within 30 days prior to Visit 2, or during run-in period
* Patients with known history of non compliance to medication
* Patients unable to satisfactorily use a dry powder inhaler device or perform spirometry measurements

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No